Pyxis Oncology, Inc.
Pyxis Oncology is a clinical-stage oncology company developing treatments for patients with solid tumors, with an immediate focus on head and neck squamous cell carcinoma. Its lead product candidate, micvotabart pelidotin, or MICVO, is an investigational antibody-drug conjugate designed to target EDB+FN in the tumor extracellular matrix and deliver a cytotoxic payload. Pyxis studies MICVO alone and in combination with pembrolizumab in clinical trials involving recurrent and metastatic head and neck cancer and other solid tumors. Pyxis develops oncology medicines and seeks strategic collaborations to support its pipeline. It also works to maximize value from its intellectual property and technology platforms, including its FACT platform for ADC development and APXiMAB platform for antibody discovery and development. Pyxis Oncology is headquartered in Boston, Massachusetts.
No SEC Form 4 filings for $PYXS in the last 30 days.
See all $PYXS insider activity →Wedbush kept its Outperform rating on Pyxis Oncology but reduced its price target to $7 from $8, citing a 12.5% decrease. The new target suggests a 334.8% upside from the Nov 5 close of $1.61, according to the firm.
Stifel reduced its price target for Pyxis Oncology (NASDAQ:PYXS) to $5.00 from $7.00, citing revised financing assumptions and increased dilution, while maintaining a Buy rating. The firm noted positive Phase 3 results for MICVO in second-line treatment. Other analysts, including H.C. Wainwright, Wells Fargo, and Wedbush, raised their price targets to $8.00, $19.00, and $8.00 respectively, based on promising Phase 1 trial data.
Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PYXS (Pyxis Oncology, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent PYXS coverage spans financial news, corporate actions and earnings.
Analyst downgrade suggests downside pressure on the stock.
Target cut suggests lower upside and potential near‑term price pressure.
Positive trial data and cash runway suggest upside pressure.
The announcement may generate modest buying interest as investors anticipate early-phase data.
The stake increase signals confidence and may support the stock price.
AlphAI scores every news story that mentions PYXS with an AI model for sentiment and relevance, and aggregates insider trades from Pyxis Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush kept its Outperform rating on Pyxis Oncology but reduced its price target to $7 from $8, citing a 12.5% decrease. The new target suggests a 334.8% upside from the Nov 5 close of $1.61, according to the firm.
Stifel reduced its price target for Pyxis Oncology (NASDAQ:PYXS) to $5.00 from $7.00, citing revised financing assumptions and increased dilution, while maintaining a Buy rating. The firm noted positive Phase 3 results for MICVO in second-line treatment. Other analysts, including H.C. Wainwright, Wells Fargo, and Wedbush, raised their price targets to $8.00, $19.00, and $8.00 respectively, based on promising Phase 1 trial data.
Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2
Pyxis Oncology (PYXS) announced presentations on micvotabart pelidotin (MICVO) at the EORTC-NCI-AACR Symposium. The company will present a Phase 1 study on MICVO monotherapy for recurrent/metastatic head and neck cancer, and two posters on preclinical research. MICVO targets extradomain-B of fibronectin and has received FDA Fast Track Designation.
GordonMD Global Investments, a 10% owner of Pyxis Oncology (NASDAQ:PYXS), acquired 5.5 million shares and 7.5 million warrants on October 1, 2026, at $0 per share. The stock trades at $2.19, down 23% in a week but up 48% over six months. Analysts raised price targets to $8-$19, citing positive clinical trial data for its cancer treatment.
GordonMD Global Investments LP purchased 5,517,000 indirectly-held shares of Pyxis Oncology, Inc. (PYXS) on 2026-10-01. Filed jointly with GordonMD Long Biased Master Fund LP (10% owner), GordonMD Long Biased GP LLC (10% owner) and Gordon Craig D (10% owner).
Pyxis Oncology (PYXS) closed a public offering, raising $110M upfront. The deal includes milestone-linked warrants that could add $172.6M if exercised, totaling $282.6M. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering involved new and existing institutional investors.
Pyxis Oncology (PYXS) raised $102.8M in a public offering of common stock and warrants, priced at $2.90 per share. The offering was led by Leerink, Guggenheim, and Wells Fargo. Proceeds will support clinical development and corporate needs, including the Phase 3 Headliner trial.
Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 29, 2026, Pyxis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as repre
Pyxis Oncology (PYXS) plans a public offering of common stock, pre-funded warrants, and common warrants. Proceeds will fund clinical trials, including MICVO for head and neck cancer, and general corporate purposes. The offering is subject to market conditions and stockholder approval. Leerink, Guggenheim, and Wells Fargo are joint bookrunners.
